Key Takeaways
- Base business margin jumps, but volumes slip: Core EBITDA margin rose to 39% from 34% YoY, driven by a richer product mix, even as base business revenue fell 8% on volume degrowth in key products.
- Cenexi EBITDA breakeven pushed out again: The European subsidiary is now targeting Q3 FY26 for an EBITDA-positive quarter, a delay from the prior Q4 FY25 guide, after an unannounced French regulatory inspection disrupted production.
- U.S. Enoxaparin shipments missed the quarter: A 12% quantity decline in Enoxa and Ketorolac, plus a missed Saudi tender shipment, dragged U.S. volumes; management frames both as timing issues, with shipments planned for Q4.
- Complex generics are the new margin engine: 27 new molecules launched in the U.S. this year, 30 SKUs of which are first-time launches with gross margins above 65%, reshaping the portfolio away from lower-margin legacy products.
- What to watch next quarter: Whether the promised Enoxa and Saudi tender shipments actually land, the pace of Cenexi’s operational recovery post-inspection, and any concrete progress on the Shanghai Henlius biosimilar contract.
Base Business: Volume Decline, Margin Surge
- Revenue down on volumes: Base business revenue fell 8% YoY, with volume degrowth in some key products partly offset by new launches; management expects volumes to recover in coming quarters.
- Gross margin transformation: Base business gross margin improved to 63% from 56% YoY, driven by a shift toward higher-margin vial and lyophilized products versus ampoules, plus cost control measures.
- New launches carry superior economics: The 27 new molecules launched in the U.S. this year, including 30 first-time-launch SKUs, carry gross margins upwards of 65%, fundamentally improving the portfolio’s margin profile even as legacy volumes decline.
- Enoxa margin trade-off: If Enoxaparin volumes recover, overall margin as a percentage will come down, but absolute profit will grow; management is aggressively pushing complex generics and RTU launches to maintain gross margins through the mix shift.
- Chinese competition as a margin floor: For low-margin products, Chinese competitors may stay away from launching if tariffs impact them; for high-margin products, the impact is lesser, potentially protecting Gland’s improved margin structure.
Shyamakant Giri: "So, this year, if you see our new launches in the U.S., we have launched 27 molecules and 39 SKUs of which 30 SKUs are first-time launches in the U.S. and the gross margin there is upwards of 65% or so."
Cenexi: Inspection Fallout and Delayed Breakeven
- Breakeven timeline slips: Cenexi is now targeting Q3 FY26 for an EBITDA-positive quarter, pushed from the prior Q4 FY25 guide; the delay stems from an unannounced ANSM inspection at the Fontenay site that consumed three weeks of production time and triggered corrective measures causing further output loss.
- Q4 FY25 expected to stay weak: Management anticipates weaker performance for the January-March quarter, as the inspection’s ripple effects continue to weigh on manufacturing activity.
- Revenue threshold unchanged: The path to breakeven still requires pushing revenue beyond the EUR 200 million threshold; a new high-speed ampoule line at Fontenay, now operational, will increase capacity by 40% to 5 crore units.
- Belgium site still healing: Orders from a new customer were deferred from Q3 to Q4 FY25, and an earlier lyophilizer breakdown continued to affect production; restoration is expected in H1 FY26.
- Validation batches progress: Validation batches for two products were finalized in Q3 and will move into commercial production in Q1, contributing to the revenue ramp toward breakeven.
Srinivas Sadu: "We are estimating now Q3 FY '26 could be EBITDA positive quarter. One is we mentioned about the inspection that happened last quarter. So, we lost a few weeks because of that. So that's kind of impacting the next quarter numbers a bit and last quarter numbers a bit. So that's the main reason."
U.S. Business: Shipment Timing Masks Underlying Demand
- Volume decline is a timing issue, not demand destruction: Certain products, including Enoxaparin, were not shipped in Q3; management states these shipments are planned for Q4, which will compensate for the shortfall.
- Enoxa and Ketorolac drove the QoQ drop: U.S. Enoxa and Ketorolac volumes declined 12% in quantity variance; new launches had lower volume relative to the lost Enoxa volume, but the new products carry better margin profiles, improving overall margin mix.
- Saudi tender also missed: The Saudi tender revenue was absent in Q3 because hospital allotment was delayed; it is a low-margin business, so its absence positively impacted the margin profile.
- U.S. Enoxa supply expected to resume in Q4: Management confirmed U.S. Enoxa supply should restart in the current quarter.
Srinivas Sadu: "Even U.S. we didn't supply Enoxa. I think there's a decline of -- I would give you a steer percentage. But 12% down in terms of quantity variance for Enoxa and Ketorolac, the other product -- 2 products."
New Growth Vectors: Biosimilars, GLP-1, and Complex Partnerships
- Dr. Reddy’s biologics collaboration: A collaboration agreement leverages Gland’s biologics manufacturing facility at Genome Valley, Hyderabad; incremental revenue is expected starting FY26.
- Shanghai Henlius term sheet signed: A nonbinding CDMO collaboration term sheet covers a secondary manufacturing site for key biosimilar products; a full contract is still to be signed, with revenue likely in the FY27-FY28 timeframe.
- Biosimilar capacity expansion under evaluation: To meet demand from the Henlius term sheet, Gland is evaluating expansion of drug substance capacity by an additional 15 KL, at an estimated cost of $80 million to $100 million.
- GLP-1 CDMO revenue starting small: Two customers and three product contracts are in place; revenues will start appearing slowly in FY26, with the majority expected from the end of FY27 as patents expire in RoW and Canada.
- GLP-1 cartridge capability: The syringe line being installed this year has the capability to fill sterile cartridges; a separate INR 200 crore investment for 10 crore cartridge capacity is under evaluation, with an 18-month project completion timeline.
- MAIA Pharmaceuticals co-development: 15 complex formulations are under co-development, comprising 7 505(b)(2) and 8 ANDAs; commercialization is expected to begin from FY27.
- Pen/auto-injector expansion: One more line is being added this year, adding another 10 crore capacity; most spend is already incurred, with commissioning expected in 2028.
Regulatory and Operational Milestones
- U.S. FDA inspections closed: EIR received from U.S. FDA for Dundigal and Pashamylaram facilities in Hyderabad, closing large U.S. FDA inspections and removing a key overhang.
- Fontenay inspection observations received: The unannounced ANSM inspection at Fontenay resulted in observations; CAPA is being finalized for submission.
- New capacity coming online: A high-capacity ampoule line at Fontenay began production on schedule; commercial production of a new inactivated vaccine and ophthalmic gel commenced in December at Hérouville; a new prefilled syringe line installation has begun, expected operational later in 2025.
- Greenfield project on the horizon: The current manufacturing site is maxed out; management is looking at a greenfield project for the next phase of growth.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cenexi EBITDA breakeven | Achieve an EBITDA-positive quarter | Q3 FY26 |
| Cenexi full-year EBITDA positive | Deliver positive EBITDA for the full year, driven by revenue beyond EUR 200 million | Full year 2026 |
| Cenexi Belgium lyophilizer restoration | Lyophilizer production restored | H1 FY26 |
| U.S. Enoxaparin supply resumption | Shipments to resume, compensating for Q3 shortfall | Q4 FY25 |
| Saudi tender shipment | Delayed hospital allotment shipments to occur | Q4 FY25 or Q1 FY26 |
| Dr. Reddy’s biologics revenue | Incremental revenue from collaboration | Starting FY26 |
| MAIA complex formulation commercialization | Co-developed 505(b)(2) and ANDA products commercialized | Beginning FY27 |
| Shanghai Henlius biosimilar revenue | Revenue from CDMO collaboration (subject to full contract signing) | FY27-FY28 |
| GLP-1 CDMO revenue | Smaller volumes begin; majority arrives later | FY26 (small); end FY27 (majority) |
| Pen/auto-injector line expansion | Additional 10 crore capacity commissioned | 2028 |
| Cartridge capacity investment (if approved) | INR 200 crore, 10 crore cartridge capacity | 18 months from approval |
| Biosimilar drug substance expansion (if approved) | 15 KL additional capacity at $80-100 million | Under project evaluation |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Consolidated revenue | ₹1,384.1 crore, 100 bps increase in EBITDA margin YoY |
| Base business (ex-Cenexi) revenue | ₹1,012.3 crore, 8% decrease YoY |
| Consolidated EBITDA | ₹360 crore, margin of 26% vs 23% in Q3 FY24 |
| Base business EBITDA margin | 39%, vs 34% in Q3 FY24 |
| Consolidated gross margin | 67%, from 61% in Q3 FY24 |
| Base business gross margin | 63%, vs 56% in Q3 FY24 |
| Net profit | ₹204.7 crore, up 7% YoY and 25% sequentially from Q2 |
| PAT margin | 15%, improvement from 12% YoY |
| R&D expenditure | ₹43.7 crore, 4.3% of base business revenue |
| Cenexi revenue | €4.1 crore, impacted by unannounced ANSM inspection at Fontenay |
| Cenexi EBITDA | Negative ₹31.2 crore, primarily due to the ANSM inspection |
| Cenexi gross margin | 77%, vs 75% in Q3 FY24 |
| India market revenue | ₹56.2 crore, contributing 4% of total revenues |
| Rest of World revenue share | 21% of total revenues in Q3 FY25 |
| U.S. ANDA filings (cumulative) | 366 filings, 312 approvals, 54 pending |
| Global product registrations | 1,736 |
| New U.S. molecule launches in quarter | 13 molecules launched |
| Complex product portfolio progress | 9 filings completed of 19 targeted, 6 launched |
| Profit share as percentage of base business revenue | 11.7% in Q3 |
| Milestone income as percentage of base business revenue | 10.2% in Q3 |
| Net cash position (after Cenexi debt) | ₹2,412.2 crore as of Dec 31, 2024 |
| Cash flow from operations (9M FY25) | ₹588.9 crore |
| Cenexi order book | Above €60 million, including backlog carried from 2024 |
| Cenexi EBITDA breakeven guidance | Q3 FY26 (previously Q4 FY25) |
| U.S. Enoxa market share | About 6% |
| U.S. heparin market share | Around 20%–25% |
| U.S. price variance QoQ | About 1% to 2% lower |
| One-off finance cost (GST refund matter) | About ₹18 crore |